FINWIRES · TerminalLIVE
FINWIRES

Opthea Poised to Resume Trading on Australian Securities Exchange After Decision to Advance Lung Disease Drug Candidate

By

Opthea (ASX:OPT) expects to resume trading on the Australian Securities Exchange on or around Wednesday following a decision to advance its OPT-302 drug candidate for the treatment of lymphangioleiomyomatosis, according to a same-day filing with the Australian bourse.

Lymphangioleiomyomatosis is a chronic lung disease that mainly affects women, characterized by the destruction of lung tissue.

Opthea believes its scientific assets, manufacturing capabilities, and intellectual property portfolio "provide a strong foundation" for a strategy focused on the disease, where a significant unmet medical need exists.

The company has launched a staged development program over an expected 18-month period to evaluate OPT-302, it said.

Related Articles

Asia

Megaport Wins New AI Infrastructure Contracts Totaling Nearly AU$500 Million

Megaport (ASX:MP1) won four new artificial intelligence (AI) infrastructure contracts worth roughly AU$458.9 million in total, according to a Wednesday filing with the Australian bourse.The company also plans to establish an on-demand graphics processing units (GPU) pool, supported by an investment of AU$350 million, to grant enterprise customers access to AI infrastructure through contracted and consumption-based commercial models, the filing said.Additionally, the company launched a fully underwritten 1-for-3.08 pro rata accelerated non-renounceable entitlement offer to raise AU$827.3 million to secure the capital expenditure required to fulfill the new contracts and seed the GPU pool, per the filing.

$ASX:MP1
Asia

Tivan Signs AU$10 Million Option Underwriting Agreement, Raises Further AU$5 Million Via Placement

Tivan (ASX:TVN) signed an underwriting agreement with Evolution Capital to underwrite the exercise of up to AU$10 million of its listed TVNO options, exercisable at AU$0.30 each and expiring on June 30, with Regal Partners agreeing to sub-underwrite AU$7.5 million of the underwritten amount, according to a Wednesday Australian bourse filing.The company said it has also signed a binding term sheet for a AU$5 million share placement with ETFS Capital at AU$0.30 per share, with placement shares subject to a standstill arrangement upon issue.The arrangements ensure Tivan will receive a minimum of AU$15 million through mid-year, enabling it to accelerate development planning and exploration at its key projects in Australia and Timor-Leste, the filing added.

$ASX:TVN
Asia

Northern Star Resources Increases Estimated Mineral Resources, Ore Reserves

Northern Star Resources (ASX:NST) said its estimated mineral resources increased 26% to 88.9 million ounces as of March 31, while its estimated ore reserves jumped 27% to 28.4 million ounces, according to a Wednesday filing with the Australian bourse.The company is focused on its Kalgoorlie Consolidated Gold Mines operations in Western Australia, Pogo mine in Alaska, and Hemi gold project in Western Australia to support a long-term, low-cost growth pathway.The estimates include, for the first time, Northern Star's mineral resources and ore reserves for the Hemi project, which it acquired in May 2025.

$ASX:NST